

Peptide Array, Hepatitis C Virus, K3a/650, NS5b Protein

Catalog No. NR-4070

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor:

BEI Resources

Manufacturer:

Bio-Synthesis, Inc.

Product Description:

The 90-peptide array spans the NS5b protein of hepatitis C virus, K3a/650 (genotype 3a; GenPept: BAA06044).¹ Peptides are 14- to 19-mers, with 11 or 12 amino acid overlaps. Please see Table 1 for length and sequence of individual peptides.

Material Provided:

Peptides are provided lyophilized at 1 mg per vial.

Packaging/Storage:

Lyophilized peptides should be placed in a closed dry environment with dessicants and stored at -20°C or colder immediately upon arrival. A frost-free freezer should be avoided, since changes in moisture and temperature may affect peptide stability.

Solubility:

Solubility may vary based on the amino acid content of the individual peptide (see Table 2).

Reconstitution:

Lyophilized peptides should be warmed to room temperature for 1 hour prior to reconstitution. They should be dissolved at the highest possible concentration, and then diluted with water or buffer to the working concentration. Buffer should be added only after the peptide is completely in solution because salts may cause aggregation.

The most common dissolution process is 1 mg of peptide in 1 mL of sterile, distilled water. Peptides that are not soluble in water can almost always be dissolved in DMSO. Once a peptide is in solution, the DMSO can be slowly diluted with aqueous medium. Care must be taken to ensure that the peptide does not begin to precipitate out of solution. For cell-based assays, 0.5% DMSO in medium is usually well-tolerated.

Sonication and/or the addition of small amounts of dilute (10%) aqueous acetic acid for basic peptides, aqueous ammonia for acidic peptides or acetonitrile may also help

dissolution (see Table 2). These solvents may not be appropriate for certain applications, including cell-based assays.

Storage of Reconstituted Peptides:

The shelf life of peptides in solution is very limited, especially for sequences containing cysteine, methionine, tryptophan, asparagine, glutamine, and N-terminal glutamic acid. In general, peptides may be aliquoted and stored in solution for a few days at -20°C or colder. For long-term storage, peptides should be re-lyophilized and stored at -20°C or colder. If long-term storage in solution is unavoidable, peptide solutions should be buffered to pH 5–6, aliquoted and stored at -20°C or colder. Freeze-thaw cycles should be avoided.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Peptide Array, Hepatitis C Virus, K3a/650, NS5b Protein, NR-4070."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI

Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale. This material may be subject to third party patent rights.

References:

1. Yamada, N., et al. "Full-Length Sequence of the Genome of Hepatitis C Virus Type 3a: Comparative Study with Different Genotypes." *J. Gen. Virol.* 75 (1994): 3279–3284. PubMed: 7964640. GenPept: BAA06044.

ATCC® is a trademark of the American Type Culture Collection.



| Table 1 | | |
|----------|--------|----------------------------|
| Peptide | Length | Sequence |
| 1 of 90 | 16 | 1 SMSYSWTGALITPCSA 16 |
| 2 of 90 | 18 | 6 WTGALITPCSAEEEEKLPI 23 |
| 3 of 90 | 18 | 13 PCSAEEEEKLPI SPLSNL 30 |
| 4 of 90 | 18 | 20 KLPISPLSNLLRHHNLV 37 |
| 5 of 90 | 17 | 27 SNSLLRHHNLVYSTSSR 43 |
| 6 of 90 | 18 | 33 HHNLVYSTSSRSASQRQK 50 |
| 7 of 90 | 18 | 40 TSSRSASQRQKKVTFDRL 57 |
| 8 of 90 | 18 | 46 SQRQKKVTFDRLQVLDDH 63 |
| 9 of 90 | 16 | 53 TFDRLQVLDDHYKTAL 68 |
| 10 of 90 | 18 | 57 LQVLDDHYKTALQEVKER 74 |
| 11 of 90 | 18 | 64 YKTALQEVKERASRVKAR 81 |
| 12 of 90 | 18 | 71 VKERASRVKARMLSIEEA 88 |
| 13 of 90 | 18 | 78 VKARMLSIEEACALVPPH 95 |
| 14 of 90 | 17 | 85 IEEACALVPPHSARSKF 101 |
| 15 of 90 | 18 | 91 LVPPHSARSKFGYSAKDV 108 |
| 16 of 90 | 18 | 98 RSKFGYSAKDVRSLSSKA 115 |
| 17 of 90 | 18 | 105 AKDVRSLSSKAINQIRSV 122 |
| 18 of 90 | 16 | 112 SSKAINQIRSVWEDLL 127 |
| 19 of 90 | 18 | 117 NQIRSVWEDLLEDTTTPI 134 |
| 20 of 90 | 18 | 124 EDLLEDTTTPIPTTIMAK 141 |
| 21 of 90 | 17 | 131 TPTTPTTIMAKNEVFCV 147 |
| 22 of 90 | 18 | 137 TIMAKNEVFCVDPKGGGR 154 |
| 23 of 90 | 18 | 144 VFCVDPKGGGRKAARLIV 161 |
| 24 of 90 | 18 | 151 KGGKKAARLIVYPDLGVR 168 |
| 25 of 90 | 18 | 158 RLIVYPDLGVRVCEKRAL 175 |
| 26 of 90 | 18 | 165 LGVRVCEKRALYDVIQRL 182 |
| 27 of 90 | 16 | 172 KRALYDVIQRLSIETM 187 |
| 28 of 90 | 17 | 177 DVIQRLSIETMGSAYGF 193 |
| 29 of 90 | 18 | 183 SIETMGSAYGFQYSPRQR 200 |

| Table 1 | | |
|----------|--------|------------------------------|
| Peptide | Length | Sequence |
| 30 of 90 | 18 | 190 AYGFAQYSPRQRVERLLKM 207 |
| 31 of 90 | 16 | 197 PRQRVERLLKMWTSKK 212 |
| 32 of 90 | 18 | 202 ERLLKMWTSKKTPLGFSY 219 |
| 33 of 90 | 16 | 209 TSKKTPLGFSYDTRCF 224 |
| 34 of 90 | 15 | 214 PLGFSYDTRCFDSTV 228 |
| 35 of 90 | 18 | 218 SYDTRCFDSTVTGQDIRV 235 |
| 36 of 90 | 16 | 225 DSTVTGQDIRVEEAVY 240 |
| 37 of 90 | 16 | 230 GQDIRVEEAVYQCCNL 245 |
| 38 of 90 | 18 | 235 VEEAVYQCCNLEPEPGQA 252 |
| 39 of 90 | 18 | 242 CCNLEPEPGQAISLTER 259 |
| 40 of 90 | 18 | 249 PGQAISLTERLYCGGPM 266 |
| 41 of 90 | 17 | 256 LTERLYCGGPMNNSKGA 272 |
| 42 of 90 | 17 | 262 CGGPMNNSKGAQCGYLR 278 |
| 43 of 90 | 18 | 268 NSKGAQCGYLRCRASGVL 285 |
| 44 of 90 | 15 | 275 GYLRCRASGVLPTSF 289 |
| 45 of 90 | 18 | 279 CRASGVLPTSFGNTITCY 296 |
| 46 of 90 | 18 | 286 PTSFGNTITCYIKATAAA 303 |
| 47 of 90 | 17 | 293 ITCYIKATAAARAAGLR 309 |
| 48 of 90 | 17 | 299 ATAAARAAGLRNPDLV 315 |
| 49 of 90 | 18 | 305 AAGLRNPDLVCGDDLTV 322 |
| 50 of 90 | 18 | 312 DFLVCGDDLTVVAESDGV 329 |
| 51 of 90 | 18 | 319 DLVVVAESDGVDEDRTL 336 |
| 52 of 90 | 18 | 326 SDGVDEDRTLRAFTEAM 343 |
| 53 of 90 | 16 | 333 RATLRAFTEAMTRYSA 348 |
| 54 of 90 | 16 | 338 AFTEAMTRYSAAPPGA 353 |
| 55 of 90 | 18 | 343 MTRYSAAPPGDAPQPTYDL 360 |
| 56 of 90 | 18 | 350 PGDAPQPTYDLELITSCS 367 |
| 57 of 90 | 18 | 357 TYDLELITSCSSNVSVAR 374 |
| 58 of 90 | 18 | 364 TSCSSNVSVARDDKGKRY 381 |
| 59 of 90 | 18 | 371 SVARDDKGKRYYYLTRDA 388 |
| 60 of 90 | 18 | 378 GKRYYYLTRDATTPLARA 395 |
| 61 of 90 | 18 | 385 TRDATTPLARA AWETARH 402 |
| 62 of 90 | 18 | 392 LARA AWETARHTPVNSWL 409 |
| 63 of 90 | 18 | 399 TARHTPVNSWLGSII MYA 416 |
| 64 of 90 | 18 | 406 NSWLGSII MYAPTIVVRM 423 |
| 65 of 90 | 18 | 413 IMYAPTIVVRM/MMTHFF 430 |
| 66 of 90 | 19 | 420 WVRM/MMTHFFSILQSQE I 438 |
| 67 of 90 | 18 | 428 HFFSILQSQEILDRPLDF 445 |
| 68 of 90 | 18 | 435 SQEILDRPLDFEMYGATY 452 |
| 69 of 90 | 18 | 442 PLDFEMYGATYSVTPLDL 459 |
| 70 of 90 | 18 | 449 GATYSVTPLDLPAIIERL 466 |

| Table 1 | | |
|----------|--------|----------------------------|
| Peptide | Length | Sequence |
| 71 of 90 | 17 | 456 PLDLPAILERLHGLSAF 472 |
| 72 of 90 | 16 | 462 IIERLHGLSAFSVHSY 477 |
| 73 of 90 | 18 | 467 HGLSAFSVHSYSPVELNR 484 |
| 74 of 90 | 18 | 474 VHSYSPVELNRVAGTLRK 491 |
| 75 of 90 | 18 | 481 ELNRVAGTLRKLGCPPLR 498 |
| 76 of 90 | 18 | 488 TLRKLGCPPLRAWRHRAR 505 |
| 77 of 90 | 18 | 495 PPLRAWRHRARAVRAKLI 512 |
| 78 of 90 | 18 | 502 HRARAVRAKLIAQGGRAK 519 |
| 79 of 90 | 18 | 509 AKLIAQGGRAKICGLYLF 526 |
| 80 of 90 | 18 | 516 GRAKICGLYLFNWAVRTK 533 |
| 81 of 90 | 17 | 523 LYLFNWAVRTKTKLTPL 539 |
| 82 of 90 | 17 | 529 AVRTKTKLTPLPAAGQL 545 |
| 83 of 90 | 17 | 535 KLTPLPAAGQLDLSSWF 551 |
| 84 of 90 | 15 | 541 AAGQLDLSSWFTVGV 555 |
| 85 of 90 | 18 | 545 LDLSSWFTVGVGGNDIYH 562 |
| 86 of 90 | 17 | 552 TVGVGGNDIYHSVSRAR 568 |
| 87 of 90 | 17 | 558 NDIYHSVSRARTRYLLL 574 |
| 88 of 90 | 18 | 564 VSRARTRYLLLCLLLTV 581 |
| 89 of 90 | 18 | 571 YLLCLLLTVGVGIFLL 588 |
| 90 of 90 | 14 | 578 LLTVGVGIFLLPAR 591 |

| Table 2 | | |
|----------|------------|---------------------------|
| Peptide | Solubility | Solvent |
| 1 of 90 | 1 mg/mL | 100% DMSO |
| 2 of 90 | 1 mg/mL | 30% formic acid in water |
| 3 of 90 | 1 mg/mL | 50% acetic acid in water |
| 4 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 5 of 90 | 1 mg/mL | 50% acetic acid in water |
| 6 of 90 | 1 mg/mL | 50% acetic acid in water |
| 7 of 90 | 1 mg/mL | 50% acetic acid in water |
| 8 of 90 | 1 mg/mL | 50% acetic acid in water |
| 9 of 90 | 1 mg/mL | 50% acetic acid in water |
| 10 of 90 | 1 mg/mL | 50% acetic acid in water |
| 11 of 90 | 1 mg/mL | 50% acetic acid in water |
| 12 of 90 | 1 mg/mL | 50% acetic acid in water |
| 13 of 90 | 1 mg/mL | 50% acetic acid in water |
| 14 of 90 | 1 mg/mL | 50% acetic acid in water |
| 15 of 90 | 1 mg/mL | 50% acetic acid in water |

| Table 2 | | |
|----------|------------|---------------------------|
| Peptide | Solubility | Solvent |
| 16 of 90 | 1 mg/mL | 50% acetic acid in water |
| 17 of 90 | 1 mg/mL | 50% acetic acid in water |
| 18 of 90 | 1 mg/mL | 50% acetic acid in water |
| 19 of 90 | 1 mg/mL | 50% acetic acid in water |
| 20 of 90 | 1 mg/mL | 50% acetic acid in water |
| 21 of 90 | 1 mg/mL | 50% acetic acid in water |
| 22 of 90 | 1 mg/mL | 50% acetic acid in water |
| 23 of 90 | 1 mg/mL | 50% acetic acid in water |
| 24 of 90 | 1 mg/mL | 50% acetic acid in water |
| 25 of 90 | 1 mg/mL | 50% acetic acid in water |
| 26 of 90 | 1 mg/mL | 50% acetic acid in water |
| 27 of 90 | 1 mg/mL | 50% acetic acid in water |
| 28 of 90 | 1 mg/mL | 50% acetic acid in water |
| 29 of 90 | 1 mg/mL | 50% acetic acid in water |
| 30 of 90 | 1 mg/mL | Water |
| 31 of 90 | 1 mg/mL | 50% acetic acid in water |
| 32 of 90 | 1 mg/mL | 50% acetic acid in water |
| 33 of 90 | 1 mg/mL | 50% acetic acid in water |
| 34 of 90 | 1 mg/mL | 50% acetic acid in water |
| 35 of 90 | 1 mg/mL | 50% acetic acid in water |
| 36 of 90 | 1 mg/mL | 50% acetic acid in water |
| 37 of 90 | 1 mg/mL | 50% acetic acid in water |
| 38 of 90 | 1 mg/mL | 50% acetic acid in water |
| 39 of 90 | 1 mg/mL | Water |
| 40 of 90 | 1 mg/mL | 50% acetic acid in water |
| 41 of 90 | 1 mg/mL | Water |
| 42 of 90 | 1 mg/mL | 50% acetic acid in water |
| 43 of 90 | 1 mg/mL | 50% acetic acid in water |
| 44 of 90 | 1 mg/mL | 50% acetic acid in water |
| 45 of 90 | 1 mg/mL | 50% acetic acid in water |
| 46 of 90 | 1 mg/mL | 30% formic acid in water |
| 47 of 90 | 1 mg/mL | Water |
| 48 of 90 | 1 mg/mL | Water |
| 49 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 50 of 90 | 1 mg/mL | 30% formic acid in water |
| 51 of 90 | 1 mg/mL | 30% formic acid in water |
| 52 of 90 | 1 mg/mL | 100% DMSO |
| 53 of 90 | 1 mg/mL | 30% formic acid in water |
| 54 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 55 of 90 | 1 mg/mL | Water |
| 56 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 57 of 90 | 1 mg/mL | 50% acetic acid in water |

| Table 2 | | |
|----------|------------|---------------------------|
| Peptide | Solubility | Solvent |
| 58 of 90 | 1 mg/mL | Water |
| 59 of 90 | 1 mg/mL | Water |
| 60 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 61 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 62 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 63 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 64 of 90 | 1 mg/mL | 100% DMSO |
| 65 of 90 | 1 mg/mL | 50% acetic acid in water |
| 66 of 90 | 1 mg/mL | 100% DMSO |
| 67 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 68 of 90 | 1 mg/mL | 50% acetic acid in water |
| 69 of 90 | 1 mg/mL | 30% formic acid in water |
| 70 of 90 | 1 mg/mL | 50% acetic acid in water |
| 71 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 72 of 90 | 1 mg/mL | 30% formic acid in water |
| 73 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 74 of 90 | 1 mg/mL | Water |
| 75 of 90 | 1 mg/mL | Water |
| 76 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 77 of 90 | 1 mg/mL | Water |
| 78 of 90 | 1 mg/mL | Water |
| 79 of 90 | 1 mg/mL | Water |
| 80 of 90 | 1 mg/mL | Water |
| 81 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 82 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 83 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 84 of 90 | 1 mg/mL | 30% formic acid in water |
| 85 of 90 | 1 mg/mL | 30% formic acid in water |
| 86 of 90 | 1 mg/mL | 30% formic acid in water |
| 87 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 88 of 90 | 1 mg/mL | 70% acetonitrile in water |
| 89 of 90 | 1 mg/mL | 100% DMSO |
| 90 of 90 | 1 mg/mL | 50% acetic acid in water |